FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      
           
This page is updated frequently with new Platelet-related patent applications. Subscribe to the Platelet RSS feed to automatically get the update: related Platelet RSS feeds. RSS updates for this page: Platelet RSS RSS


Date/App# patent app List of recent Platelet-related patents
04/23/15
20150111889
 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists patent thumbnailnew patent Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists
The present invention relates to compounds of the formula (i), wherein the residues a, r1 to r5, z1 and z2 have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
04/23/15
20150111777
 Biomarker for early neurodegeneration detection patent thumbnailnew patent Biomarker for early neurodegeneration detection
The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of tdp-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation..
Kansas City University Of Medicine And Biosciences
04/16/15
20150105338
 Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation patent thumbnailTherapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation
The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (i): wherein r1, r2 and r3 may be independently selected from h, oh and ome; wherein x is c1 or c2 and wherein for c2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more h or oh, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow..
Provexis Natural Products Limited
04/16/15
20150104436
 Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets patent thumbnailApplication and pharmaceutical composition of preactivated and disaggregated shape-changed platelets
Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation.
Chang Gung Medical Foundation, Linkou Branch
04/16/15
20150101995
 Device and  extracting high-concentration plasma from whole blood patent thumbnailDevice and extracting high-concentration plasma from whole blood
Disclosed are a device and method of extracting high-concentration plasma from whole blood. The device comprises: a first syringe; a centrifugation tube that is connected to the first syringe in order to centrifuge whole blood received in the first syringe; a cap that is connected to the first syringe in order to re-centrifuge plasma collected in the first syringe by centrifugation of the whole blood; and a membrane filter comprising: a body that is cylindrical in shape and has a pair of spaced inlets to which the first syringe and a second syringe are to be respectively connected; a hollow membrane included in the body; and a first space formed between the body and the membrane and serving to collect components that passed through the membrane.
04/09/15
20150099716
 Maintenance of platelet inhibition during antiplatelet therapy patent thumbnailMaintenance of platelet inhibition during antiplatelet therapy
A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis.
The Medicines Company
04/09/15
20150099298
 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof patent thumbnailAntibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. .
Bayer Pharma Aktiengesellschaft
04/09/15
20150098939
 Novel antagonist antibodies and their fab fragments against gpvi and uses thereof patent thumbnailNovel antagonist antibodies and their fab fragments against gpvi and uses thereof
The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein glycoprotein vi (gpvi) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a gpvi depletion phenotype.
Sanofi
04/02/15
20150094298
 Inhibitors of protein kinases patent thumbnailInhibitors of protein kinases
The present invention is directed to compounds of formula i-ii and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.
04/02/15
20150094297
 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation patent thumbnailImidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
The present invention provides thiazole compounds of formula i wherein w, y, r0, r2, r4, r5, r6, r7, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Montreal
04/02/15
20150093770

Method and device for the determination of platelet function under flow conditions


The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other p2y(12) antagonists with antithrombotic activity as well as the determination of p2y(1) antagonists with antithrombotic activity..
Siemens Healthcare Diagnostics Products Gmbh
04/02/15
20150093543

Blood compatible surfaces


The disclosure features blood compatible articles and methods of making the articles. The methods include providing a substrate and forming a rough surface on the substrate.
Teijin Limitied
04/02/15
20150093390

Humanized and chimeric anti-factor bb antibodies and uses thereof


A method of inhibiting complement activation mediated by bb inhibitors in a subject includes administering a bb inhibitor to the subject to inhibit at least one of bb binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Theraperutics, Inc.
03/26/15
20150083973

Systems, devices, and/or methods for solar cells comprising a light amplification element


Certain exemplary embodiments can provide a method, which can comprise fabricating a system. The system can comprise a light amplification element and a charge transport element.
K Tube Technology Llc
03/26/15
20150083355

Fibrous pulp and use thereof in a composite


A composition comprises (i) an elastomer, (ii) from 1 to 5 volume % of fibrous pulp, the pulp having a specific surface area of from 7 to 11 sq.m./g and the fiber having a fiber length of from 0.5 to 1.1 mm, a tensile modulus of from 2.5 to 130 gpa, and a tensile strength of from 1 to 3 gpa, and (iii) from 5 to 14 volume % of yield-strain promoter in the form of fibers, needles, powder or platelets, wherein the composition has a yield strain of at least 70%, an elongation at break of at least 200%, and a yield stress of at least 4 mpa.. .
E I Du Pont De Nemours And Company
03/19/15
20150080300

Growth factor concentrate and the use thereof


Provided herein are growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates comprise decapsulated growth factors derived from platelet rich plasma..
Bestop Group Holdings Limited
03/19/15
20150079194

Systems, compositions, and methods for transplantation and treating conditions


Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation
03/19/15
20150079169

Controlled dosing of clopidogrel with gastric acid inhibition therapies


The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (ppi) and optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other.
Pozen Inc.
03/19/15
20150079153

Cell suspension and use thereof


The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between.
Avita Medical Ltd.
03/19/15
20150079142

Devices and methods for preventing platelet activation


Methods for inhibiting a biomaterial-associated thrombotic event comprise reducing the number of platelets that bind to the biomaterial, or inhibiting platelet activation, by attaching cd47 or the ig domain thereof to the surface of the biomaterial. Methods of the present invention inhibit thrombi formation on or near a biomaterial that is on the surface of an implant, medical device, tube, or therapeutic delivery vehicle.
The Children's Hospital Of Philadelphia
03/19/15
20150079045

Nprcps, pfdncs and uses thereof


Identification of a group of novel particle termed “non-platelet rna-containing particles (nprcp)” provides novel compositions, downstream products and therapeutic tools. In addition a group of mixed nprcps were identified that contain rnas and proteins.
03/19/15
20150075740

Processes for clay exfoliation and uses thereof


The present invention provides methods for producing exfoliated clay platelets from a swellable clay material. In embodiments, the method for producing exfoliated clay platelets includes providing an exfoliating agent comprising an anionic extractant, and exposing the swellable clay material to the exfoliating agent, wherein the exfoliating agent produces exfoliated clay platelets from the swellable clay material.
Nanopaper, Llc
03/05/15
20150065374

Detection of platelet-derived shed cd31


The present invention relates to various soluble forms of cd31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of cd31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed cd31 and the use of such methods as a diagnostic tool..
Assistance Publique-hopitaux De Paris
03/05/15
20150064800

Diagnostic devices, methods and systems for detecting platelet factor 4 (pf4)/heparin antibodies


The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (pf4)/heparin complex in a fluid sample. The assay utilizes an immobilized pf4/polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human pf4/heparin antibodies.
03/05/15
20150064687

Method and producing platelet rich plasma


A device and method for producing a portion of platelet rich plasma from a fluid sample obtained from a patient. The device comprises three intercommunicated portions, each portion having an internal chamber defined therein.
03/05/15
20150064238

Method and composition for enhancing the delivery of anti-platelet drugs for the treatment of acute stroke


The invention provides a method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising an anti-platelet drug and a vehicle that can reduce the binding rate of plasma proteins, so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose. By use of the neuro-protective efficacy of anti-platelet drug, the invention allows the drug to release slowly to the site of treatment by combining anti-platelet drugs with a vehicle that can reduce the binding rate of plasma proteins to effectively reduce the dose of the anti-platelet drug and consequently reduce the side effects such as hypotension caused by, administration of a high dose of the anti-platelet drugs.
03/05/15
20150064202

Humanized and chimeric anti-factor c3 antibodies and uses thereof


A method of inhibiting complement activation mediated by c3b inhibitors in a subject includes administering a c3b inhibitor to the subject to inhibit at least one of c3b binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Therapeutics, Inc.
03/05/15
20150064133

Bioactive compositions derivable from platelet concentrates, and methods for preparing and using same


The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios..
Cook General Biotechnology Llc
03/05/15
20150060363

Device and processing and producing autologous platelet-rich plasma


A system and method are provided, including an integrated single-use kit, for processing whole blood to produce platelet rich plasma. A two stage spinning membrane separator, has a first stage for receiving whole blood and separating substantially all red blood cells from plasma and platelets, and a second stage for further separating platelet rich plasma from plasma.
Fenwal Inc.
03/05/15
20150059617

Cellulose platelet compositions, methods of preparing cellulose platelet compositions and products comprising same


A composition and method of preparing a composition is presented wherein the composition comprises cellulose platelets and the cellulose platelets comprise at least 60% cellulose by dry weight, less than 10% pectin by dry weight and at least 5% hemicellulose by dry weight. The composition can be concentrated to at least 25% by weight solids content by pressing under low pressure, whilst retaining the ability to be re suspended within an aqueous medium.
Cellucomp Limited
02/26/15
20150056643

Microfluidic devices for measuring platelet coagulation and associated systems and methods


The present technology relates generally to microfluidic devices for measuring platelet coagulation, and associated systems and methods. In some embodiments, a fluidics device includes an array of microstructures including pairs of generally rigid blocks and generally flexible posts.
University Of Washington Through Its Center For Commercialization
02/26/15
20150056604

Compositions and methods for preserving platelet function


Compositions and methods for maintaining platelet functionality and extending the shelf-life of platelets are described. Platelet preservation compositions include a photosensitizer and a plurality of platelet preservation agents.
Biovec Transfusion, Llc
02/26/15
20150056602

Apheresis platelets with fixed residual plasma volume


Methods and systems for obtaining platelets are disclosed. Platelets are collected in a pre-determined volume of plasma and a determined amount of a combined storage medium including the pre-determined amount of plasma and a volume of a synthetic additive solution..
Fenwal, Inc.
02/26/15
20150052723

Methods and systems for fabricating platelets of a monochromator for x-ray photoelectron spectroscopy


Methods and systems for fabricating platelets of a monochromator for x-ray photoelectron spectroscopy (xps) are disclosed. For example, a method of fabricating a platelet of a monochromator for x-ray photoelectron spectroscopy involves placing a crystal on a stage of an x-ray measuring apparatus, the crystal having a top surface.
02/19/15
20150050677

Methods and systems for measuring whole blood platelet reactivity


The invention relates to a novel approach and related methods and systems, which provide accurate and easily implemented measurement and analyses of whole blood platelet reactivity, and impact on treatment thereof.. .
University Of Massachusetts Medical School
02/19/15
20150050641

Method for the enumeration of mammalian micronucleated erythrocyte populations, while distinguishing platelets and/or platelet-associated aggregates


A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains dna (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
Litron Laboratories, Ltd.
02/19/15
20150050331

Method for making a topical composition comprising growth factors derived from human umbilical cord blood platelets


The present invention is directed to a method of making a stable composition comprising growth factors, which may include platelet derived growth factors and transforming growth factors. The method comprises providing human umbilical cord blood plasma containing platelets, but substantially free of whole blood cells, and lysing the platelets to extrude growth factors into the plasma.
Novo Solutions Md, Llc
02/19/15
20150050325

Organic compounds


The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery..
The Rockefeller University
02/12/15
20150044574

Polymer electrolyte membranes for rechargeable batteries


An electrolyte membrane for use in a rechargeable battery includes a polymer layer and platelet particles, where the polymer layer is reinforced with a fiber mat, and the polymer layer retains an electrolyte. A rechargeable battery uses the membrane in a position between a positive electrode and negative electrode where the membrane serves as an ion conductor for the battery..
02/12/15
20150044469

Mineral composition made from a mixed solid phase of calcium and magnesium carbonates, preparing same and use thereof


A mineral composition made from a mixed solid phase of calcium and magnesium carbonates, method of preparing same and use thereof. A mineral composition made from a mixed solid phase of calcium and magnesium carbonates, formed from a crystallised calcium portion and a crystallised magnesium portion in the form of platelets, the crystals of the calcium portion and those of the magnesium portion being aggregated in the form of composite aggregates, said aggregates themselves being at least partially agglomerated, said calcium portion comprising at least one carbonate chosen from the group consisting of calcite, aragonite and the mixtures thereof, said magnesium portion comprising hydromagnesite in platelet form, said mixed solid phase having a bulk density less than or equal to 250 kg/m3, and greater than or equal to 80 kg/m3, measured according to standard en 459.2..
S.a. Lhoist Recherche Et Developpement
02/05/15
20150038492

Benzamides and nicotinamides as syk modulators


The present invention is directed to compounds of formula i and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.
02/05/15
20150038449

Maintenance of platelet inhibition during antiplatelet therapy


A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis.
The Medicines Company
02/05/15
20150037821

Methods of identifying hit-antibodies and pf4 antagonists and cell lines for use therein


Methods and cells or cell lines for identifying antibodies or fragments thereof that activate heparin-induced thrombocytopenia (hit) are described. The methods comprise contacting a hematopoietic cell or cell line that comprises, in operative association, the platelet receptor fcyriia under the control of a suitable promoter, and a reporter construct comprising a reporter gene under the control of a promoter and transcription factor, which transcription factor is regulated downstream of the signaling cascade of activated fcyriia, with a test sample from a mammalian subject; a platelet factor 4 (pf4), a wild-type or variant of pf4 or a fragment thereof; and heparin; and detecting or measuring the level of reporter gene expression..
The University Of Birmingham
02/05/15
20150037431

Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities


Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (prp) composition are provided. Any type of arrhythmia may be treated using the prp composition.
Bioparadox, Llc
02/05/15
20150037430

Formulation of a blood composition that is rich in platelet and/or growth factors and contains gelled proteins, and a its preparation


Formulation comprising, or derived from, an initial blood composition, wherein the formulation is rich in platelets and/or growth factors and proteins originating from the initial blood composition, and wherein the proteins are in a gelled state. The invention also refers to method for preparing the formulation, comprising the steps of heating and then cooling the initial blood composition at certain temperatures and times.
Biotechnology Institute, I Mas D, S.l.
02/05/15
20150037239

Dispersion and retrieval of de-bundled nanotubes


A method for dispersing nanotubes, comprising forming a nanocomposite solution with associated nanotubes and nanoplatelets, mixing a surfactant to the nanocomposite solution, separating the nanocomposite in solution, wherein the nanotubes remain suspended in the surfactant solution, and isolating the nanotubes in solution. In certain instances, the method further comprises functionalizing the nanotubes in solution..
The Texas A&m University System
02/05/15
20150034990

Controlling led emission pattern using optically active materials


A light emission device comprising a light emitting element, a wavelength conversion (e.g. Phosphor) element, and a filter that reduces color over angle (coa) effects by at least partially reflecting light from the light emitting element that strike the filter at near-normal angles of incidence.
Koninklijke Phillips N.v.
01/29/15
20150031567

Mirna biomarkers for ulcerative colitis


Methods for diagnosing inflammatory bowel disease and ulcerative colitis using mirna biomarkers for these diseases are provided. Differential expression of the mirna biomarkers in blood fractions, e.g., platelets, of diseased individuals as compared to expression levels in normal individuals indicates the presence of ibd or ulcerative colitis.
Genisphere, Llc
01/29/15
20150030578

Method for producing activated autologous platelet rich and platelet poor plasma and methods of use


A method and kit to produce activated autologous platelet rich and platelet poor plasma (aaprpp) and methods of use to treat pain. The method to produce aaprpp generally comprising (1) obtaining whole blood from patient; (2) centrifuging whole blood in a collection tube; (3) extracting platelet rich and platelet poor plasma mixture from collection tube; and (4) transferring platelet rich and platelet poor plasma mixture to an activation tube containing at least one platelet aggregator and at least one platelet activator to obtain a resulting platelet concentration.
01/29/15
20150030500

Irradiation inactivating pathogens and/or leukocytes in a biological fluid and process


The invention relates to an irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid such as a platelet suspension and/or plasma comprising: a casing (2), a support member (3) for carrying at least one irradiation bag (19) containing the biological fluid, a light source (4) comprising two banks of light (5, 6) disposed above and below the support member (3), and an agitating system (25) for moving the support member (3), the light source generating uvc light of suitable intensity to inactivate pathogens and/or leukocytes and the agitation system moving the support member in an orbital path with predetermined amplitude and rotational frequency suitable to expose the whole biological fluid to uvc.. .
Maco Pharma S.a.
01/29/15
20150027900

Production of graphene


A method for the production of graphene and graphite nanoplatelet structures having a thickness of less than 100 nm in an electrochemical cell, wherein the cell comprises: (a) a negative electrode which is graphitic; (b) a positive electrode which may be graphitic or another material; and (c) an electrolyte which is ions in a solvent where the cations are organic ions and metal ions; and wherein the method comprises the step of passing a current through the cell.. .
The University Of Manchester
01/22/15
20150025223

System and producing interleukin receptor antagonist (ira)


The present invention relates to a system and method for producing high levels of autologous il-1ra cytokine, comprising: a blood collection vessel (1), a cover (4), a portion of separation gel (2), an anticoagulant portion (3), a plasma collection syringe comprising a sharp needle (9), a buffy coat collection syringe (11) and an incubation tube with cover (15). The vessel is adapted such that, when containing the whole blood (5), and centrifuged after treatment, yields separation fractions comprising, a first fraction of rbcs sediment (6), a second fraction of said gel (2), a third fraction comprising wbcs, platelets and), and fourth fraction of plasma solution (8)..
Estar Technologies Ltd
01/22/15
20150025030

Hydroxysafflor yellow a sodium and preparation as well as application thereof


A hydroxysafflor yellow a sodium compound as shown in a formula (i) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material.
Zhejiang Yongning Pharmaceutical Co Ltd
01/22/15
20150024431

Thrombopoietic compounds


The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal..
Amgen Inc.
01/22/15
20150024042

Phased dosing of clopidogrel


The present invention provides for novel formulations of clopidogrel to provide for phased/spaced release for use as improved antiplatelet therapies in stroke and cardiovascular indications.. .
Pozen Inc.
01/22/15
20150023976

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited
01/22/15
20150023975

Par-1 activation by metalloproteinase-1 (mmp-1)


Matrix metalloproteases (mmps) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (par-1) by endogenous platelet mmp-1 collagenase on the surface of platelets.
Tufts Medical Center, Inc.


Popular terms: [SEARCH]

Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













1.2097

3245

459196 - 0 - 71